The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy

Purpose Prognostic impact of lymphadenectomy during radical nephroureterectomy (RNU) for urothelial carcinoma of the upper urinary tract (UTUC) is controversial. Our aim was to assess the impact of lymph node status (LNS) on survival in patients treated by RNU. Methods In our multi-institutional, re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:World journal of urology 2013-02, Vol.31 (1), p.189-197
Hauptverfasser: Ouzzane, Adil, Colin, Pierre, Ghoneim, Tarek P., Zerbib, Marc, De La Taille, Alexandre, Audenet, François, Saint, Fabien, Hoarau, Nicolas, Adam, Emilie, Azemar, Marie Dominique, Bensadoun, Henri, Cormier, Luc, Cussenot, Olivier, Houlgatte, Alain, Karsenty, Gilles, Maurin, Charlotte, Nouhaud, François Xavier, Phe, Véronique, Polguer, Thomas, Roumiguié, Mathieu, Ruffion, Alain, Rouprêt, Morgan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Prognostic impact of lymphadenectomy during radical nephroureterectomy (RNU) for urothelial carcinoma of the upper urinary tract (UTUC) is controversial. Our aim was to assess the impact of lymph node status (LNS) on survival in patients treated by RNU. Methods In our multi-institutional, retrospective database, 714 patients with non-metastatic UTUC had undergone RNU between 1995 and 2010. LNS was tested as prognostic factor for survivals through univariate and multivariable Cox regression analysis. Results Median age was 70 years [interquartile range (IQR), 60–75] with median follow-up of 27 months (IQR, 10–50). Overall, lymphadenectomy was performed in 254 patients (35.5 %). Among these patients, 204 (80 %) had negative lymph nodes (pN0) and 50 (20 %) had positive lymph nodes (pN1/2). The 5-year cancer-specific survival (CSS) was 81 % [95 % confidence interval (CI), 73–88 %] for pN0 patients, 85 % (95 % CI, 80–90 %) for pNx patients and 47 % (95 % CI, 24–69 %) for pN1/2 patients ( p  
ISSN:0724-4983
1433-8726
DOI:10.1007/s00345-012-0983-1